

Table. *N*-4,4,4-Trifluoro-3-oxo-1-butenyl Derivatives of Amino Acids **3a–f** and Dipeptides **4a–c, e, f**

Product	Yield (%)	$[\alpha]_{578}^{20}$ (<i>c</i> = 1, MeOH)	mp (°C)	Molecular Formula ^a	IR (KBr) ν (cm ⁻¹)	¹ H-NMR (CDCl ₃ /TMS) δ , <i>J</i> (Hz)
3a	88	−17.6	102	C ₇ H ₈ F ₃ NO ₃ (211.1)	1740, 1652, 1555	1.62 (d, 3H, <i>J</i> = 7.5), 4.18 (dq, 1H, <i>J</i> ≈ 7.5), 5.5 (d, 1H, <i>J</i> = 7.2), 7.15 (dd, 1H, <i>J</i> = 7.2, 13.5), 9.45 (br s, 1H), 10.4 (br s, 1H)
3b	89	−87.7	89	C ₉ H ₁₂ F ₃ NO ₃ (239.2)	1738, 1657, 1558	—
3c	75	−89.9	114	C ₁₃ H ₁₈ F ₃ NO ₅ (325.3)	1752, 1740, 1653, 1556	—
3d	70	−105.0	101	C ₁₀ H ₁₂ F ₃ NO ₅ (283.2)	1755, 1745, 1655, 1555	2.15 (m, 2H), 2.4 (m, 2H), 3.6 (s, 3H), 4.25 (t, 1H, <i>J</i> = 7), 5.4 (d, 1H, <i>J</i> = 7.5), 7.3 (dd, 1H, <i>J</i> = 7.5, 13), 8.9 (br s, 1H), 10.4 (br s, 1H)
3e	72	−249.2	152	C ₁₃ H ₁₂ F ₃ NO ₃ (287.2)	1752, 1653, 1564	3.0 (dd, 1H, <i>J</i> = 15.5, 9.3), 3.35 (dd, 1H, <i>J</i> = 15.5, 4.5), 4.12 ("td", 1H, <i>J</i> = 9.3, 4.5), 5.21 (d, 1H, <i>J</i> = 7.5), 6.56 (dd, 1H, <i>J</i> = 7.5, 13.1), 7.0–7.4 (m, 5H), 10.3 (br s, 1H)
3f^b	88	−215.5	103	C ₉ H ₁₀ F ₃ NO ₃ (237.2)	1770, 1650, 1560	2.05 (m, 2H), 2.3 (m, 2H), 3.3–3.5 (m, 2H), 4.4 (t, 1H, <i>J</i> = 7), 5.34 (d, 1H, <i>J</i> = 12.5), 8.15 (d, 1H, <i>J</i> = 12.5), 10.4 (br s, 1H)
4a	89	+0.8	124	C ₁₁ H ₁₅ F ₃ N ₂ O ₄ (296.2)	1766, 1700, 1665, 1595, 1568	1.2 (t, 3H, <i>J</i> = 7), 1.5 (d, 3H, <i>J</i> = 7.8), 4.0 (m, 2H), 4.2 (q, 2H, <i>J</i> = 7), 4.3 (m, 1H), 5.4 (d, 1H, <i>J</i> = 7), 6.3 (br s, 1H), 7.1 (dd, 1H, <i>J</i> = 13, 7), 10.1 (br s, 1H)
4b	80	−44.5	120	C ₁₃ H ₁₉ F ₃ N ₂ O ₄ (324.3)	1750, 1685, 1657, 1580, 1562	—
4c	94	−22.6	152	C ₂₂ H ₃₅ F ₃ N ₂ O ₆ (480.5)	1730, 1715, 1673, 1652, 1580, 1562	—
4e	82	−116.5	123	C ₂₃ H ₂₃ F ₃ N ₂ O ₄ (448.4)	1730, 1690, 1655, 1570, 1553	—
4f	91	+15.7	162	C ₁₈ H ₂₇ F ₃ N ₂ O ₄ (392.4)	1760, 1685, 1650, 1580, 1560	—

^a Satisfactory microanalyses obtained: C ± 0.30, H ± 0.17, F ± 0.32.^b ¹³C-NMR (50.327 MHz, CDCl₃/TMS): δ = 23.3 (β -CH₂), 29.4 (γ -CH₂), 48.5 (δ -CH₂), 64.8 (α -CH), 90.0 (α -CH=), 117.7 (q, *J* = 289 Hz, CF₃), 155.3 (β -CH=), 172.9 (CO₂H), 177.5 (q, *J* = 33 Hz, COCF₃).

4a–c, e, f, were isolated in high yield. They are stable, colorless crystalline compounds. There are various attributes that it is necessary for a protecting group in peptide synthesis to possess; in particular, easy and selectivity of the deprotection step is of great importance. The removal of the *N*-4,4,4-trifluoro-3-oxo-butenyl protecting group from dipeptides occurs under the same conditions as that of the deprotection of protected amino acids **3a–f**. Yields of the dipeptides ester hydrochlorides exceed 90 %. The 4,4,4-trifluoro-3-oxo-1-butenyl group is the vinyllog of the known trifluoroacetyl protecting group. *N*-Trifluoroacetyl amino acid derivatives have been shown to have a tendency towards racemization. A variation on the Weygand's test for determination of the extent of racemization using gas chromatography, consists in recognition of D-phenylalanine containing peptide formation in accordance with the reaction:

Z-Leu-Phe + Val-OBu-*t* → Z-Leu-Phe-Val-OBu-*t*, various activators can be used. To clarify whether racemization of *N*-4,4,4-trifluoro-3-oxo-1-butenyl derivatives has occurred during peptide synthesis, we have synthesized dipeptide *rac*-**4e** starting from racemic *N*-4,4,4-trifluoro-3-oxo-1-butenylphenylalanine (**3e**) and peptide L,L-**4e** starting from L-**2e**. The ¹⁹F-NMR spec-

trum of **4e** has a singlet at δ = 77.5 from by the trifluoromethyl group. In the spectrum of the *rac*-**4e** there are two singlets with close chemical shift values ($\Delta\delta$ = 0.01), belonging to the trifluoromethyl groups of the diastereoisomeric dipeptides. After removal of the 4,4,4-trifluoro-3-oxo-1-butenyl group dipeptides L,L-**5e** and *rac*-**5e** were examined by HPLC. It was shown that the dipeptide L,L-**5e** (L-Phe-L-Phe-OMe) contains not more than 0.5 % of the D-isomer (D-Phe-L-Phe-OMe) as admixture. Therefore, we can claim that 4,4,4-trifluoro-3-oxo-1-butenyl group does not promote racemization during peptide bond formation process in the presence of DCC even if no nucleophilic additions are used.⁶

In conclusion we consider 4-ethoxy-1,1,1-trifluoro-3-buten-2-one (**1**) to be a suitable reagent for the *N*-terminal protection of amino acids in peptide synthesis. The advantages of **1** are that it is readily available, the protection and deprotection steps are simple, and free from racemization, stability of the crystalline *N*-4,4,4-trifluoro-3-oxo-1-butenyl derivatives.

All the amino acids and hydrochlorides of amino acid esters used in the synthesis are from "Reanal", DCC is from "Fluka". 4-Ethoxy-1,1,1-trifluoro-ethoxyvinyl-3-buten-2-one (**1**) was prepared accord-

ing to literature procedure.¹ The hydrochlorides of the ester dipeptides **5b**, **e** and of the amino acids **2a**, **b**, **f** after removal of the 4,4,4-trifluoro-3-oxo-1-butenyl group are hygroscopic solids homogeneous under HPLC conditions. The isomeric composition of dipeptide **5e** was determined by reversed phase HPLC (LKB, column 150 × 3.3 mm Separon SGX.C₁₈, 5 mm, mobil phase MeOH/0.1% v/v TFA (7:3) flow 0.3 mL/min, $k = 1.3$ for L,L **5e** and $k = 2.2$ for D,L **5e**, detection at 220 nm). Observed rotations at 578 nm were obtained at 20°C using a Polamat-A polarimeter and IR spectra were obtained using a Specord M-80 spectrophotometer. NMR spectra were obtained using a Bruker WP 200 MHz spectrometer.

N-4,4,4-Trifluoro-3-oxo-1-butenyl Amino Acids 3a–f; General Procedure:

To a solution of **2** (14 mmol) in 1 N NaOH (14 mL) is added **1** (2.35 g, 14 mmol) and the mixture is stirred 1–3 h at r.t. (22°C) until the solution is homogeneous. The solution is acidified using 6 N aq HCl to pH 3.0, is extracted with Et₂O (3 × 15 mL). The ethereal layer is dried (MgSO₄), hexane (5 mL) is added and the solvent is removed by evaporation. The solid is crystallized from hexane/Et₂O (5:1) (Table).

Dipeptides 4a–c, e, f; General Procedure:

Hydrochloride of the amino acid ester (5.2 mmol) and Et₃N (0.72 mL, 5.1 mmol) are added with stirring to the solution of Tfav amino acid (**3a–c**, **e**, **f**; 5 mmol) in CH₂Cl₂ (17 mL). To the cooled (–10°C) mixture DCC (1.35 g, 6.5 mmol) is added. After 1 h at 0°C, the mixture is allowed to warm to r.t., filtered and the solvent is evaporated. The residue is dissolved in Et₂O/EtOAc (1:1)

(30 mL). The solution is washed with 1 N HCl (2 × 20 mL), H₂O (2 × 40 mL), 1 N NaHCO₃ (2 × 20 mL), 25% NaCl (2 × 30 mL) and dried (MgSO₄). The solvent is evaporated and crude product is crystallized from Et₂O/hexane (1:1) (Table).

Removal of the 4,4,4-Trifluoro-3-oxo-1-butenyl Protecting Group; General Procedure:

The Tfav amino acids **3a**, **b**, **f** and dipeptides **4b**, **e** (0.5 mmol) are dissolved in dioxane/3 N HCl (2:5, 10 mL). The mixture is allowed to stand for 10 h at r.t., then extracted with Et₂O (2 × 50 mL), the H₂O layer evaporated. The hygroscopic, solid hydrochlorides amino acids **2a**, **b**, **f** and esters of dipeptides **5b**, **e** are obtained.

Received: 21 August 1990

- (1) Hojo, M.; Masuda, R.; Kokuryo, Y.; Shioda, H.; Matsuo, S. *Chem. Lett.* **1976**, 499.
- (2) Gerus, I.I.; Gorbunova, M.G.; Vdovenko, S.I.; Yagupol'skii, Yu.L.; Kukhar, V.P. *Zh. Org. Khim.* **1990**, 26, 1877.
- (3) Greene, T.W. *Protective Groups in Organic Chemistry*, John Wiley & Sons, New York, 1981, p. 278.
- (4) Hiskey, R.G.; Southard, G.L. *J. Org. Chem.* **1966**, 31, 3582.
- (5) Boissonas, R.A.; Guttmann, St.; Jaquenoud, P.-A. *Helv. Chim. Acta* **1960**, 43, 1349.
- (6) König, W.; Geiger, R. *Chem. Ber.* **1970**, 103, 788.